TY - JOUR
T1 - Risk prediction models with incomplete data with application to prediction of estrogen receptor-positive breast cancer
T2 - Prospective data from the Nurses' Health Study
AU - Rosner, Bernard
AU - Colditz, Graham A.
AU - Iglehart, J. Dirk
AU - Hankinson, Susan E.
N1 - Funding Information:
Support for this project was provided by National Institutes of Health grants P01 CA87969, CA49449, and CA089393 (Specialized Programs of Research Excellence in Breast Cancer). GAC was supported in part by a clinical research professorship from the American Cancer Society. We acknowledge Marion McPhee for programming assistance and Jessica Bugg for preparation assistance.
PY - 2008/7/3
Y1 - 2008/7/3
N2 - Introduction: A number of breast cancer risk prediction models have been developed to provide insight into a woman's individual breast cancer risk. Although circulating levels of estradiol in postmenopausal women predict subsequent breast cancer risk, whether the addition of estradiol levels adds significantly to a model's predictive power has not previously been evaluated.Methods: Using linear regression, the authors developed an imputed estradiol score using measured estradiol levels (the outcome) and both case status and risk factor data (for example, body mass index) from a nested case-control study conducted within a large prospective cohort study and used multiple imputation methods to develop an overall risk model including both risk factor data from the main cohort and estradiol levels from the nested case-control study.Results: The authors evaluated the addition of imputed estradiol level to the previously published Rosner and Colditz log-incidence model for breast cancer risk prediction within the larger Nurses' Health Study cohort. The follow-up was from 1980 to 2000; during this time, 1,559 invasive estrogen receptor-positive breast cancer cases were confirmed. The addition of imputed estradiol levels significantly improved risk prediction; the age-specific concordance statistic increased from 0.635 ± 0.007 to 0.645 ± 0.007 (P < 0.001) after the addition of imputed estradiol.Conclusion: Circulating estradiol levels in postmenopausal women appear to add to other lifestyle factors in predicting a woman's individual risk of breast cancer.
AB - Introduction: A number of breast cancer risk prediction models have been developed to provide insight into a woman's individual breast cancer risk. Although circulating levels of estradiol in postmenopausal women predict subsequent breast cancer risk, whether the addition of estradiol levels adds significantly to a model's predictive power has not previously been evaluated.Methods: Using linear regression, the authors developed an imputed estradiol score using measured estradiol levels (the outcome) and both case status and risk factor data (for example, body mass index) from a nested case-control study conducted within a large prospective cohort study and used multiple imputation methods to develop an overall risk model including both risk factor data from the main cohort and estradiol levels from the nested case-control study.Results: The authors evaluated the addition of imputed estradiol level to the previously published Rosner and Colditz log-incidence model for breast cancer risk prediction within the larger Nurses' Health Study cohort. The follow-up was from 1980 to 2000; during this time, 1,559 invasive estrogen receptor-positive breast cancer cases were confirmed. The addition of imputed estradiol levels significantly improved risk prediction; the age-specific concordance statistic increased from 0.635 ± 0.007 to 0.645 ± 0.007 (P < 0.001) after the addition of imputed estradiol.Conclusion: Circulating estradiol levels in postmenopausal women appear to add to other lifestyle factors in predicting a woman's individual risk of breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=53249114119&partnerID=8YFLogxK
U2 - 10.1186/bcr2110
DO - 10.1186/bcr2110
M3 - Article
C2 - 18598349
AN - SCOPUS:53249114119
SN - 1465-5411
VL - 10
JO - Breast Cancer Research
JF - Breast Cancer Research
IS - 4
M1 - R55
ER -